EP2892535
Aðferð til viðbótar krabbameinsmeðhöndlunar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
30.8.2013EP published:
22.9.2021EP application number:
13835019.4
EP translation filed:
23.11.2021Grant published:
15.12.2021EPO information:
European Patent Register
Max expiry date:
29.8.2033Expiry date:
29.8.2026Next due date:
31.8.2026
Title:
METHOD OF ADJUVANT CANCER TREATMENT
Timeline
Today
30.8.2013EP application
22.9.2021EP Publication
23.11.2021Translation submitted
15.12.2021Registration published
29.8.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
LAQUERRE, SylvieAddress:
King of Prussia, Pennsylvania 19406, US
Name:
LEBOWITZ, Peter F.Address:
Research Triangle Park, North Carolina 27709, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201261696375 PDate:
4.9.2012Country:
US
Classification
Categories:
A61K 31/519, A61K 31/506, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 10
Paid: 27.7.2022
Expires: 29.8.2023
Payer: Árnason Faktor ehf.
Number: 11
Paid: 26.7.2023
Expires: 29.8.2024
Payer: Árnason Faktor ehf.
Number: 12
Paid: 23.7.2024
Expires: 29.8.2025
Payer: Árnason Faktor ehf.
Number: 13
Paid: 11.8.2025
Expires: 29.8.2026
Payer: Árnason Faktor ehf.